imlunestrant (Inluriyo)
Jump to navigation
Jump to search
Indications
- adults with estrogen receptor-positive, human epidermal growth factor 2 (HER2)- negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Dosage
- 400 mg once a day 2 hours befor food or 1 hour after food
Laboratory
- Guardant360 CDx assay a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with imlunestrant.
Mechanism of action
More general terms
References
- ↑ US Food & Drug Administration, Sept 25, 2025 FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast
- ↑ Jhaveri KL, Neven P, Casalnuovo ML et al for the EMBER-3 Study Group. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. N Engl J Med. 2025 Mar 27;392(12):1189-1202. PMID: https://pubmed.ncbi.nlm.nih.gov/39660834 Clinical Trial.